Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Squalamine Lactate + Ranibizumab in Neovascular AMD
NCT02511613Phase 2Withdrawn
- Sponsor
- Ohr Pharmaceutical, Inc.
- Start
- Jul 2015
- Primary completion
- Apr 2016
- Modality
- Multivalent & Scaffold-Based Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of squalamine in neovascular age-related macular degeneration (NVAMD), sponsored by Ohr Pharmaceutical, Inc.. Planned start Jul 2015; status: withdrawn.
02
Drugs
squalamine
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02511613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02511613.